Minimally modified low density lipoprotein is biologically active in vivo in mice

F Liao1, J A Berliner, M Mehrabian

  • 1Department of Medicine, University of California School of Medicine, Los Angeles 90024-1679.

Insights

Minimally modified LDL (MM-LDL) triggers inflammatory responses in vivo, increasing macrophage colony-stimulating factor (CSF) and monocyte chemotactic protein-1 (MCP-1) mRNA. This suggests MM-LDL acts as an inflammatory agent contributing to early atherosclerosis.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Atherosclerosis Research

Background:

  • Minimally modified low-density lipoprotein (MM-LDL) induces inflammatory responses in vascular cells in vitro.
  • These responses include monocyte adherence to endothelial cells (EC) and production of colony-stimulating factors (CSF) and monocyte chemotactic protein-1 (MCP-1).

Purpose of the Study:

  • To investigate the biological activity of MM-LDL in vivo.
  • To determine if MM-LDL can induce inflammatory responses in a living organism.

Main Methods:

  • Microgram quantities of MM-LDL were injected into mice.
  • Serum CSF activity was measured, and tissues were analyzed for mRNA expression using Northern analysis.
  • Experiments included using a mouse strain resistant to bacterial lipopolysaccharide (LPS) to rule out contamination.

Main Results:

  • MM-LDL injection significantly increased serum CSF activity (7-26 fold) compared to native LDL.
  • The induced CSF activity was primarily due to macrophage CSF.
  • MM-LDL injection markedly induced mRNA for JE, the mouse homolog of MCP-1, in various tissues.
  • Results were similar in LPS-resistant mice, indicating MM-LDL's effect is independent of LPS contamination.

Conclusions:

  • MM-LDL is biologically active in vivo.
  • MM-LDL acts as an inflammatory agent.
  • MM-LDL may contribute to the early stages of atherosclerosis.